{"id":"virulizin","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Virulizin is based on a modified vaccinia virus engineered to replicate preferentially in tumor cells with defective interferon signaling. The virus directly lyses cancer cells and triggers anti-tumor immune responses. It is designed to work synergistically with chemotherapy and other cancer treatments.","oneSentence":"Virulizin is an oncolytic virus therapy that selectively infects and destroys cancer cells while sparing normal tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:35.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer (in combination with chemotherapy)"},{"name":"Other solid tumors (investigational)"}]},"trialDetails":[{"nctId":"NCT00040092","phase":"PHASE3","title":"A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer","status":"COMPLETED","sponsor":"Aptose Biosciences Inc.","startDate":"2002-07","conditions":"Pancreatic Cancer","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Virulizin®","genericName":"Virulizin®","companyName":"Aptose Biosciences Inc.","companyId":"aptose-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Virulizin is a treatment that has been studied in combination with standard chemotherapy for pancreatic cancer. A clinical trial (NCT00040092) that tested the effectiveness of Virulizin in combination with standard chemotherapy for pancreatic cancer has been completed.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}